RN Mobile Menu


Rheumatology Network

Biologics Don’t Always Work for Fatigue

Rheumatoid arthritis-associated fatigue might best be treatd with treat-to-target therapy, research suggests. Biologics offer minimal relief from fatigue.  (©Photographee.eu/Shutterstock.com)

Recent Content


The European League Against Rheumatism (EULAR) issued new gout treatment guidelines this week, the first since 2006.

Michael Schweitz, M.D.

Rheumatologists face unique challenges not fully addressed in CMS' Quality Payment Program, says CSRO's Dr. Michael Schweitz. Dr. Schweitz addresses these challenges in this blog post.

Prem N. Ramkumar, M.D.

Prem N. Ramkumar, M.D., the author of a recent analysis on readmission rates in TJA, speaks with Rheumatology Network about why readmission rates matter.


Patient self-monitoring of DMARD therapy can lead to significant reductions in health care use, researchers show.


Biologics only slightly reduce fatigue in rheumatoid arthritis (RA) patients, a systematic review suggests.


Rheumatoid arthritis patients using adalimumab don’t face higher risks for adverse health events, researchers said in a recent study. The new study also reinforces the benefit for these patients of receiving the flu vaccine.

Today’s therapeutic practices in rheumatology could one day go the way of the rotary telephone due to advances in imaging, proteomics and other areas.

By clicking Accept, you agree to become a member of the UBM Medica Community.